AbnomX is pleased to welcome PRECIRIX, a clinical-stage biotechnology company developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The single-domain antibody targets the cancer in minutes after IV infusion anywhere in the body. PRECIRIX will use the Antibody-Extractor™ algorithms with dedicated VHH functionality to...
While we were onboarding a slew of new users, we have also been busy upgrading our lead software platform. Let’s start with our favorite new feature: the Antibody Sequence Editor. One of our most highly requested features. Antibody-Extractor can now display antibody sequences in an interactive graphical...
AbnomX is pleased to welcome QVQ, a company providing extensive expertise in each step of lead panel VHH development, ranging from immunization, selection and screening to large scale production. QVQ will use the Antibody-Extractor™ algorithms with dedicated VHH functionality to strengthen its services to its...
AbnomX welcomes BAC B.V., a part of Thermo Fisher Scientific, among its growing list of users of the Antibody-Extractor™. BAC is the original developer of the CaptureSelect affinity chromatography products, based on Camelid-derived single domain [VHH] antibody fragments. BAC can now make good use of the...
In this use case we describe a novel in-silico antibody discovery methodology called “In vitro maturation”. The methodology was successfully used by the company argenx....
AbnomX is pleased to welcome the University of Lisbon as a new user of Antibody-Extractor....
The development team of AbnomX launched version 8.0 of antibody-extractor, its lead immunoinformatics product. The latest version of this software platform for antibody discovery comes with multiple new features....